AbbVie Inc (NYSE:ABBV) – Leerink Swann raised their FY2019 earnings per share estimates for AbbVie in a note issued to investors on Thursday. Leerink Swann analyst G. Porges now anticipates that the company will post earnings per share of $9.37 for the year, up from their prior estimate of $8.36. Leerink Swann currently has a “Buy” rating and a $106.00 target price on the stock.
AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The firm had revenue of $7 billion for the quarter, compared to analysts’ expectations of $7 billion. During the same period in the prior year, the business posted $1.21 earnings per share. The business’s revenue was up 8.8% compared to the same quarter last year.
AbbVie (NYSE:ABBV) traded down $1.11 during trading on Monday, reaching $105.38. The company’s stock had a trading volume of 5,095,199 shares, compared to its average volume of 4,520,000. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08. The firm has a market capitalization of $167,990.00, a price-to-earnings ratio of 25.58, a P/E/G ratio of 1.22 and a beta of 1.53. AbbVie has a one year low of $59.27 and a one year high of $106.97.
The company also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.70%. The ex-dividend date of this dividend is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio is 68.93%.
In other news, insider Laura J. Schumacher sold 145,510 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $96.71, for a total transaction of $14,072,272.10. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Henry O. Gosebruch sold 18,300 shares of the company’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $90.55, for a total value of $1,657,065.00. Following the transaction, the insider now directly owns 81,287 shares in the company, valued at approximately $7,360,537.85. The disclosure for this sale can be found here. Insiders have sold 494,676 shares of company stock worth $47,237,938 in the last ninety days. 0.23% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Pratt Collard Advisory Partners LLC bought a new stake in AbbVie in the fourth quarter valued at about $851,000. MHI Funds LLC bought a new stake in AbbVie in the fourth quarter valued at about $2,509,000. Spearhead Capital Advisors LLC bought a new stake in AbbVie in the fourth quarter valued at about $2,647,000. Comprehensive Portfolio Management LLC bought a new stake in AbbVie in the fourth quarter valued at about $479,000. Finally, Armstrong Henry H Associates Inc. increased its holdings in AbbVie by 2.4% in the fourth quarter. Armstrong Henry H Associates Inc. now owns 25,441 shares of the company’s stock valued at $2,460,000 after purchasing an additional 600 shares during the last quarter. 69.22% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “FY2019 Earnings Forecast for AbbVie Inc (ABBV) Issued By Leerink Swann” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.com-unik.info/2018/01/23/fy2019-earnings-forecast-for-abbvie-inc-abbv-issued-by-leerink-swann.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.